as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,526.4
Change
+28.8 (1.92%)
Open
₹1,505.0
Prev. Close
₹1,497.6
Day High
₹1,540.2
Day Low
₹1,477.0
Volume Analysis
Traded
463,324
Delivered
117,563
Delivery %
25.37%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (22.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (120.4%)
- •Strong 3-year revenue growth (64.1%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,615.26 | ₹1,577.73 | ₹1,552.06 | ₹1,514.53 | ₹1,488.86 | ₹1,451.33 | ₹1,425.66 |
| Fibonacci | ₹1,577.73 | ₹1,553.59 | ₹1,538.67 | ₹1,514.53 | ₹1,490.39 | ₹1,475.47 | ₹1,451.33 |
| Camarilla | ₹1,543.78 | ₹1,537.99 | ₹1,532.19 | ₹1,514.53 | ₹1,520.61 | ₹1,514.81 | ₹1,509.02 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+9.49%
1 Month
+15.41%
3 Months
+38.96%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹62.3
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
5.06%
Net margin 11.34% × asset turnover 0.36x × equity multiplier 1.24x
Company Overview
Sector
Healthcare
Market Cap
₹17,111 Cr
P/E (TTM)
236.0
ROE
15.6%
Book Value
₹125.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Molbio Diagnostics Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%). Strong 3-year EPS growth (120.4%).
TopFund Score — Fundamentals Quality
53/100 — AverageData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 148 days to 116 days
- −Stock is trading at 11.9 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026
Submission of Newspaper Adverstisement of Un-audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026
CRISIL report shows IPO proceeds utilized as planned for capex; no deviations for quarter ended September 30, 2026.
Audio recording of earnings call for Q2 and H1 FY2026-27 results made available on website.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Sales + | 100 | 580 | 561 | 408 | 259 |
| Expenses + | 116 | 413 | 402 | 308 | 215 |
| Operating Profit | -16 | 167 | 159 | 101 | 44 |
| OPM % | -16.16% | 28.86% | 28.31% | 24.63% | 16.97% |
| Other Income + | 1 | 1 | 5 | 3 | 6 |
| Interest | 4 | 7 | 12 | 11 | 9 |
| Depreciation | 12 | 14 | 20 | 17 | 23 |
| Profit before tax | -31 | 148 | 132 | 76 | 18 |
| Tax % | -23.43% | 27.68% | 27.32% | 30.53% | 56.0% |
| Net Profit + | -24 | 107 | 96 | 53 | 8 |
| EPS in Rs | -2 | 10 | 8 | 5 | 1 |
| Raw PDF | — | — | — | — | — |
| YoY Sales growth | — | — | — | 310 | -55 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 1,271 | 776 | 327 | 837 | 1,020 | 1,446 |
| Expenses + | 676 | 457 | 286 | 602 | 760 | 1,126 |
| Operating Profit | 595 | 319 | 40 | 234 | 260 | 320 |
| OPM % | 47.0% | 41.0% | 12.0% | 28.0% | 26.0% | 22.0% |
| Other Income + | 1 | 5 | 8 | -49 | -4 | 9 |
| Interest | 35 | 25 | 6 | 14 | 18 | 33 |
| Depreciation | 12 | 42 | 19 | 41 | 45 | 64 |
| Profit before tax | 549 | 258 | 23 | 130 | 194 | 231 |
| Tax % | 25.0% | 27.0% | 32.0% | 36.0% | 29.0% | 29.0% |
| Net Profit + | 410 | 187 | 16 | 84 | 139 | 164 |
| EPS in Rs | 36 | 17 | 1 | 9 | 13 | 15 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | — | -39 | -58 | — | 22 | 42 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 333 | 681 | 737 | 821 | 966 | 1,158 | 1,429 |
| Borrowings + | 257 | 105 | 57 | 184 | 147 | 450 | 390 |
| Other Liabilities + | 215 | 85 | 123 | 211 | 346 | 496 | 498 |
| Total Liabilities | 806 | 874 | 920 | 1,218 | 1,461 | 2,115 | 2,329 |
| Fixed Assets + | 55 | 182 | 189 | 289 | 290 | 536 | 520 |
| CWIP | 100 | 0 | 0 | 2 | 27 | 11 | 18 |
| Investments | 9 | 9 | 54 | 6 | 46 | 6 | 6 |
| Other Assets + | 643 | 683 | 676 | 921 | 1,099 | 1,562 | 1,785 |
| Total Assets | 806 | 874 | 920 | 1,218 | 1,461 | 2,115 | 2,329 |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 11 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 344 | 98 | 68 | 10 | 287 | 50 |
| Cash from Investing Activity + | -142 | -87 | -51 | -45 | -123 | -54 |
| Cash from Financing Activity + | -192 | -20 | 31 | -32 | -26 | 276 |
| Net Cash Flow | 10 | -9 | 48 | -67 | 138 | 273 |
| Free Cash Flow | 212 | 35 | 55 | -7 | 232 | 1 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 78 | 53 | 251 | 23 | 141 | 38 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2026 | |
|---|---|
| Public | 38.04% |
| Promoters | 41.29% |
| FII | 1.59% |
| DII | 19.09% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Molbio Diagnostics Ltd (this stock) | 17,111 | 236.0 | 11.89 | 15.6% |
| Poly Medicure Limited | 17,041 | 53.9 | 5.22 | 9.8% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
| Cohance Lifesciences Ltd | 17,511 | 359.0 | 4.49 | 4.89% |
| Pfizer Ltd | 17,601 | 115.0 | 12.74 | 19.8% |
| Alivus Life Sciences Ltd | 17,803 | 50.6 | — | — |
| Caplin Point Lab Ltd. | 17,863 | 25.9 | 4.58 | 20.9% |
Which Mutual Funds Hold Molbio Diagnostics Ltd?
Frequently Asked Questions about Molbio Diagnostics Ltd
Molbio Diagnostics Ltd (MOLBIO) closed at ₹1,526.4 on NSE on 19 November 2026, up 28.8 (1.92%) from the previous close.
Molbio Diagnostics Ltd trades on the NSE (National Stock Exchange of India) under the symbol MOLBIO.
Molbio Diagnostics Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 236.0.
Molbio Diagnostics Ltd has a dividend yield of 0.0%.
Molbio Diagnostics Ltd's 52-week high is ₹1,687.0 and its 52-week low is ₹926.0.
Molbio Diagnostics Ltd has a market capitalisation of ₹17,111 crore.
Molbio Diagnostics Ltd has a TopFund Quality Score of 53/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Molbio Diagnostics Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.